ACTRN12611001053910招募中1 期
A multi-centre, prospective, randomised pilot study of intravenous minocycline, 200mg 12 hourly for 5 doses, compared with standard care, in patients with ischaemic stroke treated with intravenous tissue plasminogen activator (tPA).A strategy to reduce haemorrhagic transformation
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 80 Years（—）
- 性别
- All
入选标准
- •Subjects must meet the standard inclusion criteria for use of intravenous tPA, be at least 18 years of age and provide informed consent.
排除标准
- •Standard exclusion criteria for routine use of tPA
- •The critera for excluding use of tPA, as per the WA protocol for administration of intravenous tPA are;
- •1. Uncertainty about time of stroke onset (eg. patients awakening from sleep)
- •2. Coma or severe obtundation with fixed eye deviation and complete hemiplegia
- •3. Hypertension: systolic blood pressure greater than or equal to 180mmHg; or diastolic blood pressure >110mmHg on repeated measures prior to study.
- •4. Clinical presentation suggestive of subarachnoid haemorrhage even if the CT scan is normal
- •5. Presumed septic embolus
- •6. Patient having received a heparin medication within the last 48 hours and has elevated APTT or has a known hereditary or acquired haemorrhagic diathesis (eg. INR or APTT greater than normal). Known lupus anticoagulant is not a contraindication to alteplase.
- •7. INR >1.5 Known advanced liver disease, advanced right heart failure, or anticoagulation, and INR > 1.5 (no need to wait for INR result in the absence of the former three conditions)
- •8. Known platelet count <100,000 uL
- •9. Serum glucose is < 2.8mmol/l or >22.0 mmol/l
- •Relative contra-indications;
- •1. Severe neurological impairment with NIHSS score >22
- •2. Age >80 years
- •3. CT evidence of extensive middle cerebral artery (MCA) territory infarction (sulcal effacement or blurring of grey-white junction in greater than 1/3 of MCA territory)
- •4. Stroke or serious head trauma within the past 3 months where the risks of bleeding are considered to outweigh the benefits of therapy
- •5. Major surgery within the last 14 days (consider intra-arterial thrombolysis)
- •6. Patient has known history of intracranial haemorrhage, subarachnoid haemorrhage, known intracranial arteriovenous malformation or previously known intracranial neoplasm such that, in the opinion of the clinician, the increased risk of intracranial bleeding would outweigh the potential benefits of treatment
- •7. Suspected recent (within 30 days) myocardial infarction
- •8. Recent (within 30 days) biopsy of a parenchymal organ or surgery that, in the opinion of the responsible clinician, would increase the risk of unmanageable (eg. uncontrolled by local pressure) bleeding
- •9. Recent (within 30 days) trauma with internal injuries or ulcerative wounds
- •10. Gastrointestinal or urinary tract haemorrhage within the last 30 days or any active or recent haemorrhage that, in the opinion of the responsible clinician, would increase the risk of unmanageable (eg by local pressure) bleeding
- •11. Arterial puncture at non-compressible site within the last 7 days
- •12. Concomitant serious, advanced or terminal illness or any other condition that, in the opinion of the responsible clinician would pose an unacceptable risk
- •13. Rapidly improving deficit
- •14. Seizure: If the presenting neurological deficit is deemed due to a seizure, do NOT give alteplase. If the presenting neurological deficit is related to ischaemia, consider alteplase as per protocol
- •15. Pregnancy is not an absolute contraindication. Consider referral for intra-arterial thrombolysis . (Pregnancy IS an exclusion criteria for WAIMATSS.)
- •Specific exclusion criteria for the trial;
- •1.Evidence of other significant CNS disease that interferes with assessment (eg tumor, multiple sclerosis)
- •2. Known allergy to tetracyclines/intolerance of minocycline.
- •3. Known systemic lupus erythrematosis
- •4. Idiopathic intracranial hypertension.
- •5. Concurrent treatment with Vitamin A or retinoids.
研究者
相似试验
已完成
1 期
Mantra Multi Arm Surgical Robotic System - Clinical StudyCTRI/2020/11/029053Robosurg Med Tech Pvt Ltd SS Innovations Group Company12
尚未招募
不适用
The BETTER Surgery Pilot TrialPerioperative outcomesPACTR201609001780323Clinical Research Center50
招募中
不适用
Australasian Follow-up Tracking and Enhancing Recovery after Acute Kidney Injury (AFTER-AKI)Renal and Urogenital - Kidney diseaseAcute kidney injuryACTRN12618002044202Austin Health200
进行中（未招募）
不适用
A prospective, randomized, open, multi-centre study to assess safety of PURETHAL Grasses given with a rush induction schedule to patients with allergic rhinoconjunctivitis. - PURETHAL Grasses Rush studyAllergic (IgE-mediated) rhinitis/rhinoconjunctivitis due to sensitization to grass pollenMedDRA version: 12.0Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisMedDRA version: 12.0Level: LLTClassification code 10001726Term: Allergic rhinitis due to pollenMedDRA version: 12.0Level: LLTClassification code 10053741Term: Allergenic desensitization procedureEUCTR2009-015012-18-DEHAL Allergy BV
进行中（未招募）
不适用
PURETHAL Birch Rush study.PURETHAL is indicated for specific immunotherapy (desensitisation) of IgE-mediated, inhaled allergy with symptoms of allergic rhinitis, allergic conjunctivitis and allergic bronchial asthma with an allergic background.MedDRA version: 16.0Level: LLTClassification code 10001723Term: Allergic rhinitisSystem Organ Class: 100000004855EUCTR2013-000086-36-PLHAL Allergy B.V.120